Skip to main content
Clinical Trials/CTRI/2020/05/025340
CTRI/2020/05/025340
Completed
Phase 1

Clinical trial to evaluate the safety and efficacy of ShatPlus an Ayurvedic Proprietary Medicine as an intervention in adult patients with SARS-CoV-2 infection.

BVG Life Sciences Ltd BVG Group0 sites60 target enrollmentTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Sponsor
BVG Life Sciences Ltd BVG Group
Enrollment
60
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
BVG Life Sciences Ltd BVG Group

Eligibility Criteria

Inclusion Criteria

  • SARS\-CoV\-2 positive nasopharyngeal swab
  • Mild to Moderately severe disease (NEWS score \<\= 8\)
  • Signed informed consent must be obtained and documented according to AYUSH GCP, and national/local regulations

Exclusion Criteria

  • Requiring ICU admission at screening
  • History of MI, Epileptic episodes
  • Any other comorbidity which is at critical stage at screening
  • Any other condition by which subject proves unfit from investigator perspective

Outcomes

Primary Outcomes

Not specified

Similar Trials